ArticleMaterials today. Bio2025
Acousto-optogenetics bandpass stabilizer: A programmable platform for mapping single-cell phenotypic life trajectories.
Article in Materials today. Bio, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Tunable acoustic rotation for deep biophysical phenotyping of preclinical Alzheimer's disease.Materials today. Bio · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Photobleaching-induced signal decay undermines the accuracy of fluorescence-based drug screening across multiple disease models (e.g., HER2/EGFR-targeted therapies). Traditional phototoxicity mitigation strategies, primarily through reduced illumination, inevitably compromise imaging resolution and further providing false positive/false negative. Here, we introduce an innovative active photobleaching intervention strategy to solve these problems with the potential for broad applicability across a wide range of cell species. We employ the ultra-low-frequency (500-2000 Hz) acoustic modulation to control 3D cellular rotation (precisely in x-y/y-z planes) with a linearly tunable rotational speed, establishing the first quantitative framework linking acoustic parameters to photobleaching kinetics. Our results indicate that acoustic frequency scanning exerts a bandpass-filter effect on photobleaching half-life, peaking at 1500 Hz and achieving approximately 30-fold fluorescence preservation compared to static conditions. By harnessing our newly developed Acousto-Optogenetics Bandpass Stabilizer, we transform phototoxicity into a tunable parameter, thereby enabling artifact-free drug response analysis. While maintaining maximal photostability, frequency-division multiplexing further permits real-time calcium flux monitoring during optogenetic activation. Complementing this, we engineer FlowMind, an AI-powered software, to automate single-cell dynamic library processing. As proof of concept, screening calcium channel blockers under optimal photostability conditions reveals significant variations in drug screening sensitivity. By integrating acoustic modulation with optogenetics, this paradigm not only pioneers the programmable control of photostability via acoustics, but also catalyzes a transformative shift in precision oncology, heralding a new era of patient-tailored therapeutic regimens with enhanced clinical predictability.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.